OGEDA
Ogeda (formerly named Euroscreen) is a Belgium-based, privately owned clinical-stage drug discovery company that invents and develops small molecule drug candidates targeting GPCRs. Ogeda's orally-available and proprietary lead drug candidate fezolinetant (ESN364) is currently in Phase2 clinical development for the treatment of women's health disorders. Ogeda has additional small molecules targeting GPCRs in pre-clinical development in multiple therapeutic areas including inflammatory and autoimmune diseases. Ogeda is backed by leading investors, including Vealius Biocapital II SA Sicar, Fund+ NV, SRIW SA, Capricorn Health-Tech Fund NVHT fund, BNP Paribas Fortis Private Equity Management SA. For more information, please visit: www.ogeda.com
OGEDA
Industry:
Biotechnology Health Care Health Diagnostics Pharmaceutical
Founded:
1994-01-01
Address:
Brussels, Brussels Hoofdstedelijk Gewest, Belgium
Country:
Belgium
Website Url:
http://www.ogeda.com
Total Employee:
11+
Status:
Active
Contact:
(327)134-8500
Email Addresses:
[email protected]
Total Funding:
26 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Amazon
Similar Organizations
Calimmune
Calimmune is a clinical-stage gene therapy company.
Current Employees Featured
Founder
Investors List
Vesalius Biocapital Partners
Vesalius Biocapital Partners investment in Series B - Ogeda
Pierre Drion
Pierre Drion investment in Series B - Ogeda
BNP Paribas Fortis
BNP Paribas Fortis investment in Series B - Ogeda
S.R.I.W.
S.R.I.W. investment in Series B - Ogeda
Capricorn Partners
Capricorn Partners investment in Series B - Ogeda
S.R.I.W.
S.R.I.W. investment in Private Equity Round - Ogeda
Vesalius Biocapital Partners
Vesalius Biocapital Partners investment in Private Equity Round - Ogeda
Official Site Inspections
http://www.ogeda.com
- Host name: 166.117.110.61
- IP address: 166.117.110.61
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ogeda"
Ogeda - Crunchbase Company Profile & Funding
Oct 2, 2015 Ogeda (formerly named Euroscreen) is a Belgium-based, privately owned clinical-stage drug discovery company that invents and develops small molecule drug candidates …See details»
Ogeda Company Profile - Office Locations, Competitors ... - Craft
Ogeda leads the development of NK3 antagonists for the treatment of hormone-dependent pathologies in Women's Health. Its lead product, fezolinetant has shown positive results in a …See details»
News | Astellas Pharma Inc.
Tokyo, May 17, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has completed the acquisition of Ogeda SA …See details»
Astellas to Acquire Ogeda SA - Apr 2, 2017
Apr 2, 2017 Under the agreement, Astellas has agreed to pay up to a total of EUR 800 million.Astellas will make an initial payment of EUR 500 million in consideration of 100% of the …See details»
Ogeda - Products, Competitors, Financials, Employees, …
Ogeda. Frequently Asked Questions (FAQ) When was Ogeda founded? Ogeda was founded in 1994. Where is Ogeda's headquarters? Ogeda's headquarters is located at 47 Rue Adrienne …See details»
Ogeda SA - Ownership and Business Overview - Mergr
Apr 3, 2017 Ogeda SA is a clinical-stage drug discovery company that invents and develops small molecule drug candidates targeting GPCRs. Ogeda's orally-available and proprietary …See details»
Ogeda Company Profile | Vilvoorde, Belgium - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Ogeda of Vilvoorde. Get the latest business insights from Dun & Bradstreet. Ogeda. D&B Business …See details»
Ogeda Company Profile 2024: Valuation, Investors, Acquisition
Ogeda General Information Description. Developer of small molecule therapeutic drugs designed to invent and develop first-in-class small molecule drugs. The company's small molecule …See details»
ogeda.com
We serve cookies. We use tools, such as cookies, to enable essential services and functionality on our site and to collect data on how visitors interact with our site, products and services.See details»
Ogeda Company Information - Funding, Investors, and More
Get information on funding, investors, industries, and more for Ogeda. See Ogeda company profile and funding data.See details»
Ogeda - Funding, Financials, Valuation & Investors - Crunchbase
Ogeda is a privately owned clinical-stage drug discovery company. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. ... How …See details»
Delving into the Latest Updates on Ogeda SA with Synapse
国内方面，豪森的HS-10384领跑国产赛道，已进入3期临床，金赛药业的GS1-144紧随其后，处于1期临床阶段。 Fezolinetant最早由比利时药企Ogeda开发，2017年安斯泰来以5亿欧元（约 …See details»
Astellas buys Ogeda after menopause drug impresses
Apr 3, 2017 Astellas will pay $500 million upfront for 100% of the equity in Ogeda, and shareholders in the privately-owned biotech will receive another $300 million if the drug meets …See details»
Astellas to acquire Ogeda SA - European Biotechnology Magazine
Apr 3, 2017 Furthermore, Ogeda s preclinical ulcerative colitis programme ESN 282 has been partnered with Merck & Co. Ogeda s third published compound ESN601 in discovery stage is …See details»
Astellas to Acquire Ogeda SA - Pharmaceutical Processing World
Apr 3, 2017 Ogeda is a clinical-stage drug discovery company that discovers and develops small molecule drugs targeting G-protein coupled receptors (GPCRs). The lead investigational …See details»
Ogeda – Vesalius Biocapital Partners Sàrl
Ogeda – Exit . New identity reflects Ogeda’s successful transition to GPCR drug discovery & development Ogeda develops drugs to validated GPCR targets in the areas of women’s …See details»
Ogeda SA: Euroscreen announces name change to Ogeda and …
Oct 21, 2016 Euroscreen announces name change to Ogeda and completion of Series B financing New identity reflects Ogeda`s successful transition to GPCR drug discovery & …See details»
Astellas to buy GPCR specialist Ogeda for €500M upfront
Apr 3, 2017 Astellas has struck a deal to buy Ogeda for €500 million ($534 million) upfront. The takeover will give Astellas a potential nonhormonal treatment for menopausal hot flashes that …See details»
Ogeda: A Biotech Company Moving from Science to Market - The …
May 11, 2021 In 1994, Euroscreen SA was born as a spin-off from the University of Brussels, before being rebranded Ogeda SA later on, in 2016. Its initial core business unit also called …See details»
QGenda | Healthcare Workforce Management Solutions
QGenda serves more than 4,500 healthcare organizations of all sizes across multiple countries. We deliver unique solutions for each type of organization and care setting. Learn how QGenda …See details»